Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 7:21 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1417–1440 of 6,233 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 1 Clear all

Conditions: Thromboelastography, Coagulation; Fetus or Newborn, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Diabetes, Gestational
Interventions: Laboratory clotting studies; Other
Lead sponsor: Arkansas Children's Hospital Research Institute; Other
Eligibility: 0 Hours to 2 Hours
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Weight Management
Interventions: GS-4571, Placebo, Omeprazole; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 134 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Miami, Florida • San Antonio, Texas • Salt Lake City, Utah

Conditions: Hepatocellular Carcinoma, Metastatic Castration Resistant Prostate Cancer, Renal Cell Carcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Squamous Cell Carcinoma of Head and Neck, Triple-Negative Breast Cancer, Urothelial Carcinoma, Cholangiocarcinoma, GastroEsophageal Cancer, Pancreatic Cancer, Sarcoma
Interventions: Part 1 TPST-1120, Part 2 TPST-1120 + nivolumab, Part 3 TPST-1120, Part 4 TPST-1120 + nivolumab; Drug
Lead sponsor: Tempest Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 11
States / cities: San Francisco, California • Miami, Florida • Baltimore, Maryland + 7 more

Conditions: Lung Cancer
Interventions: immunohistochemistry staining method, biopsy, surgery; Other · Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 1,310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2011
U.S. locations: 56
States / cities: Mobile, Alabama • Los Angeles, California • Pasadena, California + 37 more

Conditions: Lymphoma, B-cell, Lymphoma, Large B-cell, Diffuse
Interventions: brentuximab vedotin, rituximab, vincristine, cyclophosphamide, prednisone, doxorubicin; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 36
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 33 more

Conditions: Parkinson Disease
Interventions: Low-load resistance training with blood flow restriction; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 89 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer Patients, Metastatic Castration-resistant Prostate Cancer, mCRPC, mCRPC, mCRPC (Metastatic Castration-resistant Prostate Cancer)
Interventions: KTX-2001, KTX-2001 + Darolutamide (NUBEQA®); Drug
Lead sponsor: K36 Therapeutics, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 13
States / cities: San Francisco, California • Miami, Florida • Port Saint Lucie, Florida + 8 more

Conditions: Malignant Digestive System Neoplasm, Malignant Female Reproductive System Neoplasm, Malignant Genitourinary System Neoplasm
Interventions: Non-Interventional Study; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 103
States / cities: Kingman, Arizona • Fort Smith, Arkansas • Oakland, California + 81 more

Conditions: HIV Infections
Interventions: pGA2/JS7 DNA vaccine, Placebo, MVA/HIV62 vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 299 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2014
U.S. locations: 10
States / cities: Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 5 more

Conditions: Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia
Interventions: MCS-2 15 mg/day, MCS-2 30 mg/day, Placebo; Drug
Lead sponsor: Health Ever Bio-Tech Co., Ltd.; Industry
Eligibility: 40 Years and older · Male only
Enrollment: 274 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Melanoma
Interventions: Exercise Intervention, Wellness Intervention; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Breast Neoplasms, Endocrine Breast Diseases, Neoplasm Metastasis
Interventions: letrozole, lapatinib, everolimus; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older · Female only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Perimenopause
Interventions: Resistance Training Intervention; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 40 Years to 60 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
Interventions: JNJ-67571244; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 9
States / cities: Boston, Massachusetts • Detroit, Michigan • Hackensack, New Jersey + 5 more

Conditions: Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET Gene Mutation, Metastatic Solid Tumor, Advanced Solid Tumor
Interventions: TPX-0046; Drug
Lead sponsor: Turning Point Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 20
States / cities: La Jolla, California • Orange, California • Aurora, Colorado + 15 more

Conditions: COVID-19
Interventions: Emergency Ventilator Splitter; Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Stanford, California

Conditions: Myelodysplastic Syndromes, Anemia
Interventions: Ofirnoflast; Drug
Lead sponsor: Halia Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Friedreich Ataxia
Interventions: Omaveloxolone Capsules, 2.5 mg, Omaveloxolone Capsules, 5 mg, Omaveloxolone Capsules, 10 mg, Placebo, Omaveloxolone Capsules, 20 mg, Omaveloxolone Capsules, 40 mg, Omaveloxolone Capsules, 80 mg, Omaveloxolone Capsules, 160 mg, Omaveloxolone Capsules, 300 mg, Omaveloxolone Capsules, 150 mg; Drug
Lead sponsor: Biogen; Industry
Eligibility: 16 Years to 40 Years
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 7
States / cities: Los Angeles, California • Gainesville, Florida • Tampa, Florida + 4 more

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions: Bemcentinib, Cytarabine, Decitabine; Drug
Lead sponsor: BerGenBio ASA; Industry
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 2
States / cities: Iowa City, Iowa • Houston, Texas

Conditions: Relapsed and/or Refractory Multiple Myeloma (RRMM)
Interventions: TAK-981, Mezagitamab, Daratumumab and Hyaluronidase-fihj; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 12
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Atlanta, Georgia + 9 more

Conditions: Non-muscle Invasive Bladder Cancer
Interventions: PF-08052667, Sasanlimab, BCG, PF-02921367; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 294 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 55
States / cities: Birmingham, Alabama • Ruskin, Florida • Tampa, Florida + 21 more

Conditions: Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia
Interventions: 90Y-AHN-12; Biological
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 12 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Multiple Sclerosis
Interventions: Interferon beta-1b (Betaseron, BAY86-5046); Drug
Lead sponsor: Bayer; Industry
Eligibility: 33 Years and older
Enrollment: 432 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 6
States / cities: Many Locations, Alabama • Many Locations, Arizona • Many Locations, California + 3 more

Conditions: Healthy
Interventions: LY3463251, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 118 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Daytona Beach, Florida

Search by objective public record fields.

Thromboelastographic Profile in Healthy Newborns and Infants of Diabetic Mothers Using TEG6s

Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)

TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers

Prognostic Study of Metastases in Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Can Be Removed by Surgery

Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)

Low-load Resistance Training With Blood Flow Restriction in People With Parkinson's Disease

A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)

Surgical Thromboprophylaxis Practices in Oncology Patients Within the NCORP Network, STOP-VTE Study

Safety of and Immune Response to a Prime-Boost Vaccine Regimen in HIV-Uninfected Vaccine-Naive Adults

MCS in the Treatment of Lower Urinary Tract Symptoms

3-month Aerobic and Resistance Exercise Intervention for Individuals Diagnosed With Melanoma

Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer

Hemodynamics After Resistance Training

A Study of JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations

Emergency Ventilator Splitting Between Two or More Patients (COVID-19)

A Study to Evaluate Ofirnoflast in Adults With Very Low- to Intermediate-risk Myelodysplastic Syndromes Requiring Red Blood Cell Transfusions

A Study to Learn About the Effects and Safety of RTA 408 (Omaveloxolone) in People Aged 16 to 40 With Friedreich's Ataxia

A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS

A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)

A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer

AHN-12 Biodistribution in Advanced Leukemia

Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis

A Study of LY3463251 in Healthy Participants